The Goldman Sachs Group Has Lowered Expectations for Seres Therapeutics (NASDAQ:MCRB) Stock Price

Seres Therapeutics (NASDAQ:MCRB) had its price objective cut by equities research analysts at The Goldman Sachs Group from $1.00 to $0.75 in a research report issued on Friday,Benzinga reports. The firm presently has a “sell” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 8.73% from the stock’s current price.

A number of other research analysts have also weighed in on MCRB. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Stock Up 8.1 %

MCRB stock opened at $0.69 on Friday. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53. The stock’s 50 day moving average is $0.79 and its 200-day moving average is $0.83. The firm has a market capitalization of $120.10 million, a PE ratio of -3.00 and a beta of 2.19.

Institutional Trading of Seres Therapeutics

Hedge funds have recently made changes to their positions in the company. Avantax Advisory Services Inc. grew its position in shares of Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares in the last quarter. Jane Street Group LLC grew its position in Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares in the last quarter. Virtu Financial LLC grew its position in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after buying an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC grew its position in Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares in the last quarter. Finally, Northern Trust Corp grew its position in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after buying an additional 44,461 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.